INTRODUCTION
============

Telemedicine, broadly defined as the use of medical information exchanged from one site to another via electronic communications to improve a patient's clinical health status \[[@b1-jpmph-49-4-183]\], has been expected to improve simultaneously the cost of, quality of, and access to healthcare. There are over 80 systematic reviews on the effectiveness of telemedicine and more than 20 of them reporting conclusively that telemedicine is effective \[[@b2-jpmph-49-4-183]\] in such areas as mental health \[[@b3-jpmph-49-4-183]-[@b5-jpmph-49-4-183]\] and management of chronic diseases \[[@b6-jpmph-49-4-183]-[@b8-jpmph-49-4-183]\] including diabetes, heart failure, and elderly care \[[@b9-jpmph-49-4-183],[@b10-jpmph-49-4-183]\].

However, previous systematic reviews on the economic evaluation of telemedicine, based on study populations in the US, the UK, and Australia, show there is no conclusive evidence that telemedicine interventions are cost-saving or cost-effective compared to conventional health care \[[@b11-jpmph-49-4-183]-[@b14-jpmph-49-4-183]\]. In many countries, it has been reported that a large number of telemedicine programs have been started on a trial basis but discontinued for larger scale implementation due to lack of sustainable financial sources \[[@b15-jpmph-49-4-183]-[@b19-jpmph-49-4-183]\]. This is mainly because most insurers do not reimburse new types of healthcare delivery \[[@b20-jpmph-49-4-183]-[@b22-jpmph-49-4-183]\]. For this reason, several studies have stated that comprehensive cost-effectiveness studies are essential in justifying insurer coverage and reimbursement for telemedicine in the future \[[@b23-jpmph-49-4-183],[@b24-jpmph-49-4-183]\].

Japan has faced a growing proportion of elderly people amidst a declining overall population. In 2014, the proportion of the population aged 65 or older was estimated to be 25.9%---the highest proportion in the world \[[@b25-jpmph-49-4-183]\]. Currently, two major healthcare issues in Japan are the increasing total cost of healthcare and the uneven distribution of healthcare resources. The latter issue limits the access of remotely located people to sufficient healthcare services. Telemedicine is deemed to be a potential solution for these current twofold issues.

Based on the budget records issued by Japan's Ministry of Finance, we calculated public expenditure for development and pilot trials of health information technology, including telemedicine, from 2008 to 2014---the result was \$1.5 billion. Despite such enormous amounts in public subsidies for telemedicine, the literature indicated serious concern about the financial sustainability of telemedicine \[[@b26-jpmph-49-4-183],[@b27-jpmph-49-4-183]\].

Among the studies reporting the effectiveness of telemedicine experiments around the country, only a small subset of these studies conducted an economic evaluation. The absence of a cohesive body of rigorous economic evaluation studies may be one of the key obstacles to the widespread adoption, proliferation, and funding of telemedicine programs \[[@b9-jpmph-49-4-183],[@b28-jpmph-49-4-183]-[@b30-jpmph-49-4-183]\].

This study's aim was to conduct a systematic review to identify and analyze the published economic evaluations on telemedicine in Japan. This qualitative assessment has three objectives: (a) to identify whether, and in what areas, telemedicine was evaluated to achieve a favorable level of economic efficiency, that is, whether it was cost-saving or cost-effective in Japan; (b) to assess the methodological rigorousness of the economic evaluations; and (c) to discuss future studies necessary to improve the general financial sustainability of telemedicine.

METHODS
=======

This article focuses on telemedicine in broader health areas to make the results more comprehensive. Specifically, this study gathered economic evaluations of telemedicine connecting "non-specialized physicians and specialized physicians," "physicians and patients," and "public health nurses and patients."

Search Strategy
---------------

We searched the following databases: PubMed/MEDLINE, Web of Science, IEEE Xplore, Ichushi-Web database (the largest Japanese health database), and CiNii Articles (the largest Japanese database in all academic fields). All peer-reviewed articles published between January 1, 2000 and December 31, 2014 in English and Japanese were selected if they included any type of economic evaluation in monetary terms.

The inclusion criteria regarding economic evaluation were full economic evaluation \[[@b31-jpmph-49-4-183]\] (i.e., cost-minimization analysis \[CMA\], cost-effectiveness analysis \[CEA\], cost-utility analysis \[CUA\], cost-benefit analysis \[CBA\]), cost-only analysis, or benefit-only analysis. The exclusion criteria were articles that described only effectiveness or benefit in non-monetary terms and articles available only in abstract form. [Table 1](#t1-jpmph-49-4-183){ref-type="table"} shows the different and exact combinations of keywords, relating to economic evaluation and telemedicine, used in this research. We used comparable Japanese words for Japanese databases.

Review Process
--------------

The selection process for the articles involved reading the titles and abstracts of the results obtained by one of the authors. After duplicate articles were deleted, all abstracts were read for relevance based on the inclusion and exclusion criteria. The relevant full-text articles were then obtained and thoroughly read by two authors. A classification of the telemedicine types, economic-analysis types, study designs, study populations, time frames, and the selection for the final appraisal were obtained by reading both the abstracts and the entire articles. In case of any disagreement, the two authors discussed the article and one designated author made the final decision.

In order to compare a variety of studies conducted in different time periods, we made a purchasing power parity adjustment and converted all costs to 2014 US dollars using the consumer price index \[[@b25-jpmph-49-4-183]\].

Economic Evaluation Quality Assessment
--------------------------------------

We critically assessed the methodological rigorousness of the economic evaluation for each article based on the latest version of the checklist developed by Drummond et al. \[[@b31-jpmph-49-4-183]\]. This checklist was chosen partly because it was one of the most widely used assessment tools in this area, e.g., this checklist's older version was known and widely used as "the BMJ Check-List" \[[@b32-jpmph-49-4-183],[@b33-jpmph-49-4-183]\]. The most recent version of this checklist, published in 2015 \[[@b31-jpmph-49-4-183]\], contains 87 items under ten headings (detailed in [Table 2](#t2-jpmph-49-4-183){ref-type="table"}). Assessors are asked to check either "yes," "no," or "not applicable" (N/A) for each of ten subheadings according to the relative importance subjectively conferred to each item under each subheading. There is no explicit weighting for each item to calculate a single aggregated score. This checklist concentrates on full economic evaluations, but could also be used for partial economic evaluations, reports, and commentaries on economic evaluations. If items were not applicable to a specific study, a "N/A" response could be used.

Miki Akiyama and Byung-Kwang Yoo graded three studies using the criteria in order to reach consensus on the interpretation of the criteria, and Miki Akiyama graded the remaining papers.

Supplemental Estimation Based on Published Data
-----------------------------------------------

When a reviewed study reported cost and benefit but did not report the benefit-to-cost ratio (BCR) \[[@b34-jpmph-49-4-183]-[@b36-jpmph-49-4-183]\], we made a supplemental estimation of BCR by dividing the reported financial benefit by the reported cost \[[@b31-jpmph-49-4-183]\]. The financial benefit was estimated as the reduced medical care expenditure without assigning any monetary value for an improvement in health outcome.

RESULTS
=======

Summary of Identified Literature
--------------------------------

[Figure 1](#f1-jpmph-49-4-183){ref-type="fig"} shows a flowchart with the steps followed in this review. The initial screening of the electronic databases retrieved 138 titles and abstracts; after the removal of duplicates and irrelevant titles, 64 abstracts remained for screening and 29 potentially eligible full-text articles were obtained. We excluded 12 articles after reading the full text, which were judged to meet the exclusion criteria. Two were general reviews of the situation in Asia, one was a review on the methodology of economic evaluation, four were benefit analyses using the same survey data, and five papers were not peer reviewed. Eventually, 17 peer-reviewed articles containing any form of economic appraisal in monetary terms remained.

[Table 3](#t3-jpmph-49-4-183){ref-type="table"} summarizes the characteristics and key findings of the selected studies. Among these studies, 12 were published in English \[[@b34-jpmph-49-4-183]-[@b45-jpmph-49-4-183]\] and five in Japanese \[[@b27-jpmph-49-4-183],[@b46-jpmph-49-4-183]-[@b49-jpmph-49-4-183]\]. The service settings of telemedicine were categorized into two major types: those connecting physicians for specialist consultations (the MD--MD setting) \[[@b34-jpmph-49-4-183],[@b35-jpmph-49-4-183],[@b37-jpmph-49-4-183]-[@b39-jpmph-49-4-183],[@b49-jpmph-49-4-183]\] and those connecting healthcare providers and patients \[[@b27-jpmph-49-4-183],[@b36-jpmph-49-4-183],[@b40-jpmph-49-4-183]-[@b48-jpmph-49-4-183]\], which were further sub-categorized into settings connecting physicians and patients at home (the MD--Patient setting), and those connecting public health nurses and patients at home (the PhNrs--Patient setting).

Clinical disciplines within MD--MD settings included dermatological consultation \[[@b35-jpmph-49-4-183]\], pediatric medical consultation \[[@b49-jpmph-49-4-183]\], emergency radiotherapy for malignant spinal cord compression \[[@b34-jpmph-49-4-183]\], real-time computed tomography (CT) scan indication \[[@b37-jpmph-49-4-183]\], teleradiology, and telepathology \[[@b38-jpmph-49-4-183],[@b39-jpmph-49-4-183]\].

All of the 11 settings connecting healthcare providers and patients---that is, the MD--Patient setting and PhNrs--Patient setting---dealt with home-based systems with two types of functions. One function type is a stand-alone real-time video conference system for palliative care for cancer patients without continuous monitoring of vital signs \[[@b36-jpmph-49-4-183]\]. The other type, evaluated by 10 articles \[[@b27-jpmph-49-4-183],[@b40-jpmph-49-4-183]-[@b48-jpmph-49-4-183]\], monitors vital signs with equipment such as an automated sphygmomanometer and a simple electrocardiograph for home. Healthcare providers contact a patient when an algorithm for monitored data detects an abnormal vital sign. This type of system targeted lifestyle-related diseases such as high blood pressure, diabetes, stroke, and heart failure among fragile elderly patients.

Regarding the types of economic evaluation, they were classified into four types; three were CBA \[[@b34-jpmph-49-4-183],[@b40-jpmph-49-4-183],[@b48-jpmph-49-4-183]\], which provide the most useful policy implication, that is, benefit measured by monetary value compared to input cost of telemedicine. Three studies were categorized as CMA \[[@b35-jpmph-49-4-183]-[@b37-jpmph-49-4-183]\], which estimate the cost reduction by telemedicine compared to a control group---both telemedicine and control groups achieved the same level of health outcome. Four studies \[[@b27-jpmph-49-4-183],[@b43-jpmph-49-4-183]-[@b45-jpmph-49-4-183]\] measured medical expenditure saved due to telemedicine, without calculating the input telemedicine cost or showing equal health outcomes. The remaining seven studies \[[@b38-jpmph-49-4-183],[@b39-jpmph-49-4-183], [@b41-jpmph-49-4-183],[@b42-jpmph-49-4-183],[@b46-jpmph-49-4-183],[@b47-jpmph-49-4-183],[@b49-jpmph-49-4-183]\] measured willingness-to-pay (WTP) for using telemedicine. There were no CEA or CUA studies.

MD--MD Specialist Consultation
------------------------------

Out of six studies of MD--MD settings, one clinical efficacy study presented detailed estimates of both the costs and benefits of telemedicine in emergency radiotherapy for malignant spinal cord compression (MSCC), connecting between a university hospital and 10 rural hospitals \[[@b34-jpmph-49-4-183]\]. Since this study did not report the BCR, we calculated the ratios to range from 4.67 to 13.40.

There were two CMA studies regarding MD--MD specialist live consultations. One CMA study on dermatology consultation \[[@b35-jpmph-49-4-183]\] reported cost-saving of \$330 per person per week. This study's two-way sensitivity analysis indicated that the cost-saving results were sensitive to the two key parameters of travel time and consultation time. Assuming that travel time was 60 minutes and consultation time was five minutes (based on expert opinions from Japanese dermatologists), we calculated the BCR to be 1.53.

Another CMA study \[[@b37-jpmph-49-4-183]\] examined teleradiology diagnosis accuracy in an MD--MD setting. This study estimated that teleconsultation contributed to cost-saving of \$144 per reading by avoiding unnecessary enhanced CT scans.

One survey \[[@b49-jpmph-49-4-183]\] estimated the benefits of specialist teleconsultation in pediatric emergency care for primary care physicians in rural, underserved areas. These benefits were measured by inquiring about WTP among parents of children in two rural towns, that is, \$31.40 to \$33.60 per emergency department visit.

There were two studies conducted by one study group to estimate medical providers' WTP for teleradiology and telepathology \[[@b38-jpmph-49-4-183],[@b39-jpmph-49-4-183]\]. These two studies applied different statistical methods for the same set of survey data obtained from healthcare providers across Japan, who used either teleradiology or telepathology in an MD--MD setting. Their WTP estimates were \$489 to \$510 for teleradiology and \$1063 to \$1111 for telepathology per person per year.

### Healthcare providers--patient homecare

One CMA study \[[@b36-jpmph-49-4-183]\] on home-palliative care in an MD--Patient setting reported that telemedicine could reduce the frequency of physician visits from twice to once a week. The cost-saving of home palliative care with telemedicine were estimated to be \$5000 per person per year compared to conventional home care. A sensitivity analysis of this study showed their results to be sensitive to two parameters, the number of user patients and duration of service provided. Based on the reported benefit, we calculated the BCR to be 1.93.

One study group published two CBA studies on the same type of tele-homecare service operated in different regions with different financial schemes: (a) one region where a monthly fee was charged and (b) three other regions where no fee was charged because of public subsidies. Under the former scheme, the BCR was calculated to increase monotonically over time, that is, 1.07 (6-year operation) and 1.28 (11-year operation), using WTP estimates among patients in this region \[[@b48-jpmph-49-4-183]\]. Under the latter scheme, the BCR estimates in the three regions ranged from 0.54 to 0.61 \[[@b40-jpmph-49-4-183]\], indicating that telehomecare was not cost-saving.

There were four studies reporting medical expenditure saved by telehomecare connecting public health nurses and the elderly with chronic diseases in one region \[[@b27-jpmph-49-4-183],[@b43-jpmph-49-4-183]-[@b45-jpmph-49-4-183]\]. Based on the claims data, these studies showed that treatment periods were shortened by telemedicine. Their estimates of reduced medical expenditure ranged from \$148 to \$629 per case per year for lifestyle diseases \[[@b27-jpmph-49-4-183],[@b43-jpmph-49-4-183]-[@b45-jpmph-49-4-183]\]. However, the input costs of telehomecare were not shown in these four studies.

A single research team produced three survey studies and measured patients' WTP for a telehomecare system that combines vital-signs monitoring and doctor consultation. The WTP estimates were \$288, \$480, and \$520 per case per year, depending on three analytical methods \[[@b41-jpmph-49-4-183],[@b46-jpmph-49-4-183],[@b47-jpmph-49-4-183]\]. There was only one study conducted in an urban area to estimate users' WTP for home tele-health monitoring. This study, published in 2012, showed WTP as low as \$109 per patient per year \[[@b42-jpmph-49-4-183]\].

Economic Evaluation Quality Assessment
--------------------------------------

[Table 4](#t4-jpmph-49-4-183){ref-type="table"} summarizes our quality assessment of reviewed studies in terms of the ten criteria of the well-established checklist from Drummond et al. \[[@b31-jpmph-49-4-183]\]. There were only four studies \[[@b35-jpmph-49-4-183],[@b36-jpmph-49-4-183],[@b40-jpmph-49-4-183],[@b48-jpmph-49-4-183]\] that met more than eight criteria, and eleven studies met only three or fewer criteria. Studies of CBA and CMA tended to meet more criteria than studies that measured only the benefits of telemedicine. Only two studies \[[@b35-jpmph-49-4-183],[@b36-jpmph-49-4-183]\] conducted a sensitivity analysis, and hence met the two criteria of "uncertainty estimates" and "study results including all issues of concern."

### Publication bias

[Figure 2](#f2-jpmph-49-4-183){ref-type="fig"} was created to detect a potential publication bias among the reviewed papers. A bold vertical line in this figure represents a threshold BCR value of one (also called a break-even point). A plot located rightward of this threshold vertical line indicates a favorable economic efficiency level for a telehealth program evaluated in the published study. Since the plots were skewed to the right of the threshold vertical line (i.e., BCR greater than one), [Figure 2](#f2-jpmph-49-4-183){ref-type="fig"} implies a moderate bias toward publishing more studies with a higher BCR estimate for a tele-health intervention. It should be noted that our interpretation regarding such potential publication bias has limited validity due to the small number of publications with BCR estimates.

DISCUSSION
==========

To our knowledge, this is the first systematic review to summarize the economic efficiency of Japanese telemedicine services and to examine the methodological rigorousness of the economic evaluation studies conducted in Japan. Despite the small number and the diverse quality of economic evaluations of telemedicine, most of these evaluations indicated a favorable level of economic efficiency, that is, net cost-saving, reduced medical expenditure, and/or positive WTP.

Among studies on MD--MD live consultations in hospital settings, the most economically efficient telemedicine was emergency radiotherapy consultation about malignant spinal cord compression \[[@b34-jpmph-49-4-183]\]. This study's results were consistent with another effectiveness study of spinal cord compression in Canada \[[@b50-jpmph-49-4-183]\], in terms of decreasing patient transfer and shortening treatment decision time. However, the robustness of the reported BCR magnitude (\>4.67) is uncertain due to the absence of sensitivity analyses.

Another cost-saving form of telemedicine in an MD--MD hospital setting was teledermatology consultation (\$17 160 per case per year) \[[@b35-jpmph-49-4-183]\]. This study addressed parameter uncertainty and indicated that whether teledermatology is cost-saving or not depends on the travel time and consultation time of physicians \[[@b35-jpmph-49-4-183]\]. These results do not contradict the literature reporting mixed results; that is, teledermatology cost is either lower \[[@b51-jpmph-49-4-183]\] or higher \[[@b52-jpmph-49-4-183]-[@b55-jpmph-49-4-183]\] than conventional care costs.

For an MD--Patient home setting, BCR of telemedicine-combination home palliative care was estimated to be 1.93, compared to the status quo \[[@b36-jpmph-49-4-183]\]. This CMA was methodologically rigorous with regard to (a) a clear statement of the purpose and perspective of the study, (b) a detailed illustration of the cost estimation, and (c) the implementation of a sensitivity analysis. This study in Japan is one of the few studies that explicitly indicated telemedicine to be cost-saving when used to supplement in-person home visits by physicians. Similar real-time, audio-visual communication services for home palliative care have been successfully used for some years in the US \[[@b56-jpmph-49-4-183], [@b57-jpmph-49-4-183]\] and Australia \[[@b58-jpmph-49-4-183]\], while investigation in Canada \[[@b59-jpmph-49-4-183]\] and pediatric telepalliative care in Australia \[[@b60-jpmph-49-4-183]\] faced difficulties. In the US, the cost-saving of tele-palliative care was reported as due to a reduced number of home visits by nurses \[[@b56-jpmph-49-4-183]\].

Regarding telehomecare among the elderly with chronic diseases, two CBAs reported cost-saving when implemented in one region (BCR, 1.07 to 1.28) \[[@b40-jpmph-49-4-183],[@b48-jpmph-49-4-183]\] where patients' WTP was the only outcome measured. These studies did not account for the potential reduced medical expenditure due to telemedicine. It should be noted that an identical system deployed in three other regions with public subsidies showed less economic efficiency (BCR ≤0.61) due to lower WTPs (37% to 71% of the similar one-region system above) and higher system costs (186% to 195% of the one-region system) \[[@b40-jpmph-49-4-183]\]. The reason for the mixed BCR results can be partly attributed to the public subsidy rule. The restrictive rules of public subsidy are exemplified by the prohibition on carrying over the budget to a second year \[[@b40-jpmph-49-4-183]\], which may have caused over-utilization of the first year cost and hence ultimately decreased BCR.

The methodological rigorousness of the reviewed studies tended to deviate from the established guidelines for economic evaluations \[[@b31-jpmph-49-4-183],[@b32-jpmph-49-4-183],[@b61-jpmph-49-4-183]-[@b63-jpmph-49-4-183]\]. For instance, only five studies \[[@b34-jpmph-49-4-183]-[@b36-jpmph-49-4-183],[@b40-jpmph-49-4-183],[@b48-jpmph-49-4-183]\] clarified the complete cost measurements of installing and operating telemedicine, which should have been compared with reduced medical expenditure due to the implementation of a telemedicine strategy such as a home telecare system (reduced by \$148 to \$629 per case per year) \[[@b27-jpmph-49-4-183],[@b43-jpmph-49-4-183]-[@b45-jpmph-49-4-183]\] and teleradiology (\$144 per CT reading) \[[@b37-jpmph-49-4-183]\]. Therefore, other than these five studies, it seemed very difficult to determine the accurate economic efficiency level of telemedicine among the reviewed studies.

Moreover, none of the reviewed studies implemented a CEA or a CUA of the telemedicine program under focus. Therefore, it is impossible to judge whether a program is reasonably cost-effective or not when it is not cost-saving.

Another example of a common limitation among the reviewed studies is the absence or very limited application of a probabilistic analysis such as a Monte Carlo simulation in order to address the uncertainty of multiple key parameters on cost, effectiveness, and benefit, simultaneously \[[@b31-jpmph-49-4-183]\].

In addition to the small number of total publications on the topic in focus, there are even fewer studies that examined comparable types of telemedicine technology and outcomes. This limited number of studies prevented us from performing a quantitative summary of the literature, such as a meta-analysis.

We believe that the following types of future studies would be useful for an international audience as well as a Japanese one. To convince policymakers to initiate and continue public subsidies for telemedicine, researchers are expected to produce more methodologically rigorous empirical evidence, presented in a reader-friendly manner. The strongest evidence is to show cost-saving based on a CBA. Due to diverse costs and benefits depending on setting, a probabilistic analysis result is useful to report; for example, cost-saving is achieved by telemedicine in 57% of 5000 iterations in emergency departments \[[@b64-jpmph-49-4-183]\] and 37% of 1000 iterations in intensive care units \[[@b65-jpmph-49-4-183]\]. Moreover, hospital level administrators as well as policy-makers would find it easy to understand a concrete and realistic scenario; for example, treating 10 acutely ill and injured children at a rural emergency department with telemedicine will lead to annual cost-saving of \$46 620 per emergency department \[[@b66-jpmph-49-4-183]\]. These decision makers would also appreciate specific benchmarks to achieve cost-saving, such as maximum allowable cost derived from break-even analyses \[[@b65-jpmph-49-4-183]\].

Since telemedicine in a probabilistic analysis is less likely to achieve cost-saving in 100% of iterations, a CEA needs to be implemented to test whether telemedicine is reasonably cost-effective or not \[[@b31-jpmph-49-4-183]\]. To make CEA results of telemedicine comparable with other types of health care, a future study is expected to estimate an incremental cost-effectiveness ratio (ICER) with a unit of dollar value per additional quality-adjusted life year (QALY) by the US expert panel on cost-effectiveness in health and medicine \[[@b31-jpmph-49-4-183],[@b61-jpmph-49-4-183]-[@b63-jpmph-49-4-183]\]. A certain telemedicine care strategy is concluded to be cost-effective if its ICER is lower than a commonly used threshold of \$100 000 per QALY \[[@b66-jpmph-49-4-183]\]. These estimates concerning CEA are also appreciated by policymakers and insurers who are interested in maximizing health outcomes under a fixed budget.

Other than improving the methodological rigorousness of economic evaluations, our review demonstrated the importance of WTP measured among users and public subsidy rules. The measured WTP could be used as a proxy for a future user charge, which is particularly important if the WTP exceeds the actual out-of-pocket payment for telemedicine. Partly because of the difference in the surveyed populations, WTP for a similar health-monitoring telemedicine care strategy declined by 75 percentage points from 2003 to 2010 \[[@b42-jpmph-49-4-183],[@b47-jpmph-49-4-183]\]. Potential reasons for the decline include the decreased Japanese purchasing power due to long-term macro-economic recession and users' observations of continuously falling prices in other IT products and services. Thus, further studies are needed in measuring WTP under various and detailed scenarios as well as addressing the impact of public subsidy regulation on BCR. These studies could help justify increased public financial support and hence improve the financial sustainability of telemedicine programs.

CONCLUSION
==========

In conclusion, compared to the substantial resources deployed for more than 1000 telemedicine trials in Japan, very limited resources have been deployed for the economic evaluation of telemedicine trials. Although most reviewed economic evaluations reported a favorable level of economic efficiency, their methodological rigorousness tended to vary. Further economic evaluation studies in this field are needed with more advanced methodological rigorousness and expanded research scope (e.g., public subsidy regulation impacts). These future studies are expected to help convince various decision makers such as policymakers, insurers and hospital administrators to invest further resources in telemedicine. Consequently, the general financial sustainability of telemedicine is expected to improve in the long term.
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![Funnel plot for detecting publication bias. A telehealth intervention is concluded to be cost-saving (i.e., economically efficient) when BCR (X-axis in the figure) exceeds one (represented by a bold vertical line in the figure). BCR takes on any non-negative value. A higher BCR value indicates a more economically efficient health intervention. For instance, the interpretation of BCR being two is that a \$1 investment in a telehealth intervention will generate a \$2 benefit. Due to the limited number of studies reporting BCR estimates, Figure 2 includes four plots of BCR estimates in four study sites in one publication \[[@b40-jpmph-49-4-183]\]. When a reviewed paper did not report a single representive BCR estimate (e.g., mean), we calculated an average value of multiple BCR estimates.](jpmph-49-4-183f2){#f2-jpmph-49-4-183}

###### 

Search strategy

  Database^[1](#tfn1-jpmph-49-4-183){ref-type="table-fn"}^         Keywords for search
  ---------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  PubMed/MEDLINE                                                   (\"costs and cost analysis\"\[MeSH terms\] OR \"cost benefit analysis\"\[MeSH terms\] OR \"cost effectiveness\" OR \"cost utility\") AND (\"telemedicine\"\[MeSH terms\] OR telecare OR telehealth OR e-health) AND Japan
  Web of Science                                                   TS = (\"cost\$analysis\" OR \"cost\*benefit\" OR \"cost\*effectiveness\" OR \"cost\*utility\" OR \"economic evaluation\") AND TS = (telemedicine OR tele\*care OR tele\*health OR e\*health) AND TS = (Japan\*)
  IEEE Xplore                                                      (\"cost analysis\" OR \"cost benefit\" OR \"cost effectiveness\" OR \"cost utility\" OR \"economic evaluation\") AND (telemedicine OR telec are OR telehealth OR e-health) AND Japan
  Ichushi-Web^[2](#tfn2-jpmph-49-4-183){ref-type="table-fn"}^      (in Japanese) Within \"Original Article\" category, used (\"cost analysis\" OR \"cost benefit\" OR \"cost effectiveness\" OR \"cost utility\" OR \"economic evaluation\") AND (telemedicine OR telecare OR telehealth OR e-health)
  CiNii Articles^[2](#tfn2-jpmph-49-4-183){ref-type="table-fn"}^   (in Japanese) (\"cost analysis\" OR \"cost benefit\" OR \"cost effectiveness\" OR \"cost utility\" OR \"economic evaluation\") AND (telemedicine OR telecare OR telehealth OR e-health)

The index period was 2000-2014 except for IEEE Xplore, which only allowed a search of journals published after 2002.

For Japanese databases, relevant keywords were used, and the word "Japan" was not used.

###### 

A checklist for assessing the quality of economic evaluations^[1](#tfn3-jpmph-49-4-183){ref-type="table-fn"}^ \[[@b31-jpmph-49-4-183]\]

  Contain items                                                                                                                                                                               
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **1. Was a well-defined question posed in answerable form?**                                                                                                                                
                                                                                                                                                                                      1.1.    Did the study examine both costs and effects of the service(s) or programme(s) over an appropriate time horizon?
                                                                                                                                                                                      1.2.    Did the study involve a comparison of alternatives?
                                                                                                                                                                                      1.3.    Was a viewpoint for the analysis stated and was the study placed in any particular decision-making context?
                                                                                                                                                                                      1.4.    Where the patient population and any relevant subgroups adequately defined?
  **2. Was a comprehensive description of the competing alternatives given (i.e. can you tell who did what to whom, where, and how often)?**                                                  
                                                                                                                                                                                      2.1.    Were there any important alternatives omitted?
                                                                                                                                                                                      2.2.    Was (should) a do-nothing alternative (be) considered?
                                                                                                                                                                                      2.3.    Were relevant alternatives identified for the patient subgroups?
  **3. Was the effectiveness of the programme or services established?**                                                                                                                      
                                                                                                                                                                                      3.1.    Was this done through a randomised, controlled clinical trial? If so, did the trial protocol reflect what would happen in regular practice?
                                                                                                                                                                                      3.2.    Was effectiveness established through an overview of clinical studies? If so, were the search strategy and rules for inclusion or exclusion outlined?
                                                                                                                                                                                      3.3.    Were observational data or assumptions used to establish effectiveness? If so, were any potential biases recognized?
  **4. Were all the important and relevant costs and consequences for each alternative identified?**                                                                                          
                                                                                                                                                                                      4.1.    Was the range wide enough for the research question at hand?
                                                                                                                                                                                      4.2.    Did it cover all relevant viewpoints? (Possible viewpoints include the community or social viewpoint, and those of patients and third-party payers. Other viewpoints may also be relevant depending upon the particular analysis.)
                                                                                                                                                                                      4.3.    Were the capital costs, as well as operating costs, included?
  **5. Were costs and consequences measured accurately in appropriate physical units (e.g. hours of nursing time, number of physician visits, lost work-days, gained life years)?**           
                                                                                                                                                                                      5.1.    Were the sources of resource utilization described and justified?
                                                                                                                                                                                      5.2.    Were any of the identified items omitted from measurement? If so, does this mean that they carried no weight in the subsequent analysis?
                                                                                                                                                                                      5.3.    Were there any special circumstances (e.g., joint use of resources) that made measurement difficult? Were these circumstances handled appropriately?
  **6. Were the cost and consequences valued credibly?**                                                                                                                                      
                                                                                                                                                                                      6.1.    Were the sources of all values clearly identified? (Possible sources include market values, patient or client preferences and views, policy-makers' views and health professionals' judgements)
                                                                                                                                                                                      6.2.    Were market values employed for changes involving resources gained or depleted?
                                                                                                                                                                                      6.3.    Where market values were absent (e.g. volunteer labour), or market values did not reflect actual values (such as clinic space donated at a reduced rate), were adjust- ments made to approximate market values?
                                                                                                                                                                                      6.4.    Was the valuation of consequences appropriate for the question posed (i.e. has the appropriate type or types of analysis -- cost-effectiveness, cost-benefit, cost-utility -- been selected)?
  **7. Were costs and consequences adjusted for differential timing?**                                                                                                                        
                                                                                                                                                                                      7.1.    Were costs and consequences that occur in the future 'discounted' to their present values?
                                                                                                                                                                                      7.2.    Was there any justification given for the discount rate used?
  **8. Was an incremental analysis of costs and consequences of alternatives performed?**                                                                                                     
                                                                                                                                                                                      8.1.    Were the additional (incremental) costs generated by one alternative over another compared to the additional effects, benefits, or utilities generated?
  **9. Was allowance made for uncertainty in the estimates of costs and consequences?**                                                                                                       
                                                                                                                                                                                      9.1.    If patient-level data on costs or consequences were available, were appropriate statistical analyses performed?
                                                                                                                                                                                      9.2.    If a sensitivity analysis was employed, was justification provided for the form(s) of sensitivity analysis employed and the ranges or distributions of values (for key study parameters)?
                                                                                                                                                                                      9.3.    Were the conclusions of the study sensitive to the uncertainty in the results, as quantified by the statistical and/or sensitivity analysis?
                                                                                                                                                                                      9.4.    Was heterogeneity in the patient population recognized, for example by presenting study results for relevant subgroups?
  **10. Did the presentation and discussion of study results include all issues of concern to users?**                                                                                        
                                                                                                                                                                                      10.1.   Were the conclusions of the analysis based on some overall index or ratio of costs to consequences (e.g. cost-effectiveness ratio)? If so, was the index interpreted intel- ligently or in a mechanistic fashion?
                                                                                                                                                                                      10.2.   Were the results compared with those of others who have investigated the same question? If so, were allowances made for potential differences in study methodol- ogy?
                                                                                                                                                                                      10.3.   Did the study discuss the generalisability of the results to other settings and patient/client groups?
                                                                                                                                                                                      10.4.   Did the study allude to, or take account of, other important factors in the choice or decision under consideration (e.g. distribution of costs and consequences, or relevant ethical issues)?
                                                                                                                                                                                      10.5.   Did the study discuss issues of implementation, such as the feasibility of adopting the 'preferred' programme given existing financial or other constraints, and whether any freed resources could be redeployed to other worthwhile programmes?
                                                                                                                                                                                      10.6.   Were the implications of uncertainty for decision-making, including the need for future research, explored?

Assessors are asked to check either "yes," "no," or "not applicable" for each of the 10 subheadings according to the relative importance subjectively conferred to each item under each subheading.

###### 

Summary of studies

  Author (published year) \[Ref\] language                Service setting & location               Clinical discipline             Study design   Econ Eval type       Quality assess^[1](#tfn4-jpmph-49-4-183){ref-type="table-fn"}^   Perspective          Time horizon (discount) depreciation   Sample size   Cost measurement                                                                                                     Consequence measurement                                                                          Key findings (SA)                                                                                                                                        Funding source
  ------------------------------------------------------- ---------------------------------------- ------------------------------- -------------- -------------------- ---------------------------------------------------------------- -------------------- -------------------------------------- ------------- -------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------
  Hashimoto et al. (2001) \[[@b34-jpmph-49-4-183]\] ENG   MD-MDIive consultation rural hospitals   Emergency radiotherapy          ProsCoh        CBA                  6/3                                                              Health care system   1 y (no need) Not specified            1073          Initial system and operational costs for one university hospital and 10 rural hospitals including consultation fee   Recovery rate of non-ambulant patients, % of avoiding hospitalization                            Cost-saving 4.67\<BCR\<13.4                                                                                                                              Not specified
  SA: not perfumed                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Takada et al. (2003) \[[@b37-jpmph-49-4-183]\] ENG      MD-MDIive consultation rural hospitals   Diagnostic radiology            DiagAcc        CMA                  6/3                                                              Health provider      1 y (no need) Not specified            500           Only cost of films used for diagnosis and consultation fees are shown                                                Diagnosis accuracy, % of avoiding unnecessary enhanced CT                                        Cost-saving (\$144 per reading)                                                                                                                          Not specified
  No initial cost shown                                   SA: not perfumed                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Dekio et al. (2010) \[[@b35-jpmph-49-4-183]\] ENG       MD-MDIive consultation rural hospitals   Dermatology                     DiagAcc        CMA                  9/1                                                              Health provider      1 wk (no need) Not specified           107           Initial system cost and monthly costs including medical staff's fees, travel costs, and overhead office fee          Screen image diagnoses, travel time and cost saved                                               Cost-saving BCR = 1.53 (when travel/consultation time = 60 min/5 min) (\$330 saving per case per week)^[2](#tfn5-jpmph-49-4-183){ref-type="table-fn"}^   MEXT
  SA: 2-way                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Tanikawa et al. (2010) \[[@b49-jpmph-49-4-183]\] JPN    MD-MDIive consultation rural clinics     Pediatric primary care          Survey         WTP estimation       2/7                                                              Societal             1 d (no need) Not specified            263           N/A                                                                                                                  Patients' WTP for telemedicine use between remote primary pediatrician and university hospital   WTP = \$31-34 per emergency department visit                                                                                                             Not specified
  SA: not perfumed                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Miyahara et al. (2006) \[[@b38-jpmph-49-4-183]\] ENG    MD-MD stored nation-wide                 Teleradiology, telepathology    Survey         WTP estimation       1/8                                                              Health provider      1 y (no need) Not specified            622           N/A                                                                                                                  Medical institutions' WTP, for teleradiology, pathology, consultation (MD-MD)                    WTP=\$489 per person per year for teleradiology, \$1063 for telepathology                                                                                MEXT, Postal
  Saving Funds                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  SA: not perfumed                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Tsuji et al. (2006) \[[@b39-jpmph-49-4-183]\] ENG       MD-MD stored nation-wide                 Teleradiology, telepathology    Survey         WTP estimation       1/8                                                              Health provider      1 y (no need) Not specified            622           N/A                                                                                                                  Medical institutions' WTP, for teleradiology, pathology, consultation (MD-MD)                    WTP=\$510 per person per year for teleradiology, \$1111 for telepathology                                                                                JSPS, MHLW,
  Okawa                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Telecom                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Fecundation,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Postal Saving                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  SA: not perfumed                                        Funds                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Aoki et al. (2006) \[[@b36-jpmph-49-4-183]\] ENG        MD-Pt live rural home                    Palliative care                 RetCoh         CMA                  9/0                                                              Health care system   1 y (no need)                          100           Initial system cost and monthly costs including medical staff's fees and travel costs.                               Patients\' satisfaction (qualitative), travel time and cost saved                                BCR = 1.93 (\$5000 saving per case per year)^[3](#tfn6-jpmph-49-4-183){ref-type="table-fn"}^                                                             MHLW
  5 y depreciation                                        SA: 1-way and 2-way                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Tsuji et al. (2002) \[[@b48-jpmph-49-4-183]\] JPN       MD-Pt, stored rural home                 Elderly with chronic diseases   RetCoh         CBA                  8/2                                                              Societal             6-11 y (4%)                            405           Initial system and device cost and operational costs including labor fees.                                           Users' health consciousness, anxiety, and WTP for telehomecare service                           Cost-saving                                                                                                                                              MHLW
  6y depreciaticDn                                         BCR (6 y)=1.07                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
   BCR (11 y)=1.28                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  SA: not perfumed                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Tsuji et al. (2003) \[[@b40-jpmph-49-4-183]\] ENG       MD-Pt stored rural home                  Elderly with chronic diseases   RetCoh         CBA                  8/2                                                              Societal             6 y (4%)                               2333          Initial system and device cost and operational costs including labor fees.                                           Users' health consciousness, anxiety, and WTP for telehomecare service                           BCR in 4 regions ranged from 0.54 to 1.07                                                                                                                MEXT
  6y depreciaticDn                                        SA: not perfumed                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Ito et al. (2003) \[[@b46-jpmph-49-4-183]\] JPN         MD-Pt stored rural home                  Elderly with chronic diseases   Survey         WTP estimation       2/7                                                              Societal             1 mo (no need)                         498           N/A                                                                                                                  Users' health consciousness, anxiety, and WTP for telehomecare service                           WTP=\$288 per case per year for telehomecare; no difference between 2 towns after adjustment                                                             Not specified
  Not specified                                           SA: not perfumed                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Osaka et al. (2003) \[[@b47-jpmph-49-4-183]\] JPN       MD-Pt stored rural home                  Elderly with chronic diseases   Survey         WTP estimation       1/8                                                              Societal             1 mo (no need)                         348           N/A                                                                                                                  Users' health consciousness, anxiety, and WTP for telehomecare service                           WTP=\$480 per case per year for telehome care                                                                                                            Not specified
  Not specified                                           SA: not perfumed                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Tsuji et al. (2003) \[[@b41-jpmph-49-4-183]\] ENG       MD-Pt, stored rural home                 Elderly with chronic diseases   Survey         WTP estimation       1/8                                                              Societal             1 mo (no need)                         348           N/A                                                                                                                  Users' health consciousness, anxiety, and WTP for telehomecare service                           WTP=\$520 per case per year for telehome care                                                                                                            MEXT
  Not specified                                           SA: not perfumed                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Homma et al. (2012) \[[@b42-jpmph-49-4-183]\] ENG       MD-Pt stored urban home                  Elderly with chronic diseases   Survey         WTP estimation       1/8                                                              Societal             1 mo (no need)                         102           N/A                                                                                                                  Users' WTP for monitoring service                                                                WTP=\$109 per case per year for chronic care                                                                                                             Omron Health Care Co.
  Not specified                                           SA: not perfumed                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Akematsu et al. (2009) \[[@b43-jpmph-49-4-183]\] ENG    PhNrs-Pt rural home                      Elderly with chronic diseases   RetCoh         Benefit estimation   3/7                                                              Societal             10 y (not applied)                     862           N/A                                                                                                                  Medical expenditure saved by telehomecare based on receipts data of NHI                          Savings of \$148 per case per year for outpatient care with lifestyle-related illness                                                                    MHLW, MEXT, JSPS
  Not specified                                           SA: not perfumed                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Akematsu et al. (2010) \[[@b27-jpmph-49-4-183]\] JPN    PhNrs-Pt rural home                      Elderly with chronic diseases   RetCoh         Benefit estimation   3/6                                                              Societal             1 y (no need)                          862           N/A                                                                                                                  Medical expenditure saved by telehomecare based on receipts data of NHI                          Savings \$212-371 per case per year for outpatient care with heart disease, high blood pressure, and diabetes                                            Not specified
  Not specified                                           SA: not perfumed                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Akematsu et al. (2012) \[[@b44-jpmph-49-4-183]\] ENG    PhNrs-Pt rural home                      Elderly with chronic diseases   RetCoh         Benefit estimation   3/5                                                              Societal             1 y (no need)                          408           N/A                                                                                                                  Medical expenditure saved by telehomecare based on receipts data of NHI                          Savings of \$247-387 per case per year for outpatient care with chronic diseases                                                                         Not specified
  Not specified                                           SA: not perfumed                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Akematsu et al. (2013) \[[@b45-jpmph-49-4-183]\] ENG    PhNrs-Pt rural home                      Elderly with chronic diseases   RetCoh         Benefit estimation   3/7                                                              Societal             9 y (no need)                          519           N/A                                                                                                                  Medical expenditure saved by telehomecare based on receipts data of NHI                          Savings of \$629 per case per year for outpatient care with chronic diseases                                                                             Not specified
  Not specified                                           SA: not perfumed                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

Ref, reference number; Econ, economic; Eval, evaluation; SA, sensitivity analysis; ENG, English; JPN, Japanese; N/A, not applicable; NHI, National Health Insurance; BCR, benefit-to-cost ratio; CT, computed tomography; MD, medical doctor; Pt, patient, PhNrs, public health nurse; ProsCoh, prospective cohort; DiagAcc, diagnostic accuracy study; RetCoh, retrospective cohort; CBA, cost-benefit analysis; CMA, cost-minimization analysis; WTP, willingness-to-pay; MEXT, Japan's Ministry of Education, Culture Sports, Science and Technology; MHLW, Japan's Ministry of Health, Labor, and Welfare; JSPS, Japan Society for the Promotion of Science.

Quality assessment of Econ Eval: (total number of "yes"/ total number of "no") of assessment criteria in the checklist in Table 2, (yes/no) detailed in [Table 4](#t4-jpmph-49-4-183){ref-type="table"}.

Difference between "live interactive teledermatology" and "conventional clinic."

Difference between "telepalliative care combined homecare" and "homecare with eight physician visits per month, without telemedicine" when 10 patients treated simultaneously.

###### 

Quality assessment of economic evaluation^[1](#tfn7-jpmph-49-4-183){ref-type="table-fn"}^

                                                       Reference number                                                                                             
  ---------------------------------------------------- ------------------ ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- -----
  Well-defined econ question (viewpoint, comparison)   No                 No    Yes   No    No    No    Yes   Yes   Yes   No    No    No    No    No    No    No    No
  Competing alternatives                               Yes                Yes   Yes   Yes   No    No    Yes   Yes   Yes   Yes   No    No    No    Yes   Yes   Yes   Yes
  Effectiveness of the program                         Yes                Yes   Yes   Yes   Yes   Yes   Yes   Yes   Yes   Yes   Yes   Yes   Yes   Yes   Yes   Yes   Yes
  Costs and consequences inclusion                     Yes                Yes   Yes   No    No    No    Yes   Yes   Yes   No    No    No    No    No    No    No    No
  Costs and consequences measurement                   Yes                Yes   Yes   No    No    No    Yes   Yes   Yes   No    No    No    No    No    No    No    No
  Cost and consequences value credibly                 Yes                Yes   Yes   No    No    No    Yes   Yes   Yes   No    No    No    No    No    No    No    No
  Adjusted for timing and discount                     N/A                N/A   No    N/A   N/A   N/A   N/A   Yes   Yes   N/A   N/A   N/A   N/A   No    N/A   N/A   No
  Incremental analysis                                 Yes                Yes   Yes   No    No    No    Yes   Yes   Yes   No    No    No    No    Yes   Yes   Yes   Yes
  Allowance for uncertainty in the estimates           No                 No    Yes   No    No    No    Yes   No    No    No    No    No    No    No    No    No    No
  Study results including all issues of concern        No                 No    Yes   No    No    No    Yes   No    No    No    No    No    No    No    No    N/A   No
  \# of "yes"                                          6                  6     9     2     1     1     9     8     8     2     1     1     1     3     3     3     3
  \# of "no"                                           3                  3     1     7     8     8     0     2     2     7     8     8     8     7     6     6     7

N/A, not applicable.

Each column corresponds to each of the sub-headings shown in [Table 2](#t2-jpmph-49-4-183){ref-type="table"}.
